Medical Device News Magazine

James Brown PhD Appointed President of Research Grade Nucleic Acids Aldevron Business Unit

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing James Brown PhD President of its Research Grade nucleic acids business unit.

James Brown PhD will oversee Aldevron’s strategy to provide plasmids and other nucleic acids for research and preclinical applications. He will also collaborate with Aldevron’s other business units, including GMP nucleic acids, to ensure clients benefit from the company’s full spectrum of capabilities.

“Aldevron’s goal is to enable industry, academic, and government scientists with the highest quality of plasmids and RNA, regardless of their research stage,” stated Brown, adding that Aldevron is currently supporting many healthcare and agriculture research programs. “Aldevron’s service provides a strong foundation to support the great research our clients are doing.”

Aldevron has multiple facilities located in Fargo, N.D., for nucleic acid production and is adding a 189,000 square-foot facility to its existing 120,000 square feet that will be operational in the first half of 2021.

“James joined Aldevron in 2015 and has held the roles of Vice President of Corporate Development and Chief of Staff. His 25 years of biotechnology experience include over a decade in gene and cell therapy and he is a recognized expert in the field,” said Michael Chambers, founder and CEO of Aldevron. “James brings a wealth of experience and knowledge to this role and we look forward to growing with our existing clients and expanding the reach of our research solutions to new markets.”

Brown has held many leadership roles in biotechnology, and prior to Aldevron served as Vice President of Technical Operations at Regenxbio, an AAV gene therapy company. His breadth of experience includes leadership roles at MedImmune (now AstraZeneca), Meso Scale Discovery, and IGEN International.

“It has been exciting and rewarding to be part of Aldevron’s growth over the past five years and contribute to the first approvals of treatments in gene therapy,” Brown continued. “I am honored to serve in this new role with an outstanding team and we look forward to enabling the breakthrough discovery research that will lead to products and services that will make lives better.”

Brown was a National Research Council Postdoctoral Fellow at the National Institute of Standards and Technology and received his Ph.D. in biophysical chemistry from Stanford University. He received a Bachelor of Science degree in chemistry from Butler University.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”